Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lung Neoplasms 1Liver Neoplasms 1Erectile Dysfunction 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Irinotecan 58Bevacizumab 56Oxaliplatin 49Leucovorin 49Fluorouracil 49Capecitabine 45Cetuximab 44pembrolizumab 23IFL protocol 15Nivolumab 11regorafenib 10Panitumumab 10Celecoxib 8Radiotherapy 7Cyclophosphamide 7atezolizumab 6Surgical Procedures, Operative 6Gemcitabine 6Folfox protocol 6Colonoscopy 6trifluridine tipiracil drug combination 5Neoadjuvant Therapy 5Metformin 5Immunohistochemistry 5Biopsy 5tislelizumab 4spartalizumab 4durvalumab 4Trastuzumab 4Mitomycin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Colorectal Neoplasms × Tadalafil × Clear all
NCT03785210 2026-02-23

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
22 enrolled 13 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡